Nivolumab,Ipilumumab,Prmtrexed
bms
['nsclc', 'sclc', 'lcsm,(-blcsm)', 'scienceatbms', 'bms']
don t miss late-breaking data at #esmo22: exploratory pathologic analysis from a phase 3 study evaluating #neoadjuvant #immunotherapy + chemo in resectable #nsclc. can long-term outcomes be predicted? tune in live or virtually at 15:50 (cest) #lcsm 
Official Bristol Myers Squibb Twitter handle for science. Connecting researchers, scientists and healthcare professionals through science; guidelines below: